1.Implications and limitations of cellular reprogramming for psychiatric drug development.
Brian T D TOBE ; Michael G BRANDEL ; Jeffrey S NYE ; Evan Y SNYDER
Experimental & Molecular Medicine 2013;45(11):e59-
Human-induced pluripotent stem cells (hiPSCs) derived from somatic cells of patients have opened possibilities for in vitro modeling of the physiology of neural (and other) cells in psychiatric disease states. Issues in early stages of technology development include (1) establishing a library of cells from adequately phenotyped patients, (2) streamlining laborious, costly hiPSC derivation and characterization, (3) assessing whether mutations or other alterations introduced by reprogramming confound interpretation, (4) developing efficient differentiation strategies to relevant cell types, (5) identifying discernible cellular phenotypes meaningful for cyclic, stress induced or relapsing-remitting diseases, (6) converting phenotypes to screening assays suitable for genome-wide mechanistic studies or large collection compound testing and (7) controlling for variability in relation to disease specificity amidst low sample numbers. Coordination of material for reprogramming from patients well-characterized clinically, genetically and with neuroimaging are beginning, and initial studies have begun to identify cellular phenotypes. Finally, several psychiatric drugs have been found to alter reprogramming efficiency in vitro, suggesting further complexity in applying hiPSCs to psychiatric diseases or that some drugs influence neural differentiation moreso than generally recognized. Despite these challenges, studies utilizing hiPSCs may eventually serve to fill essential niches in the translational pipeline for the discovery of new therapeutics.
Animals
;
Antipsychotic Agents/pharmacology
;
*Drug Discovery
;
Humans
;
Induced Pluripotent Stem Cells/cytology/*drug effects/metabolism
;
Mental Disorders/*drug therapy/metabolism
;
*Nuclear Reprogramming
2.Correlation between Expression of Peripheral IL-17 Protein and Aggression of Bipolar Mania.
Hao-zhe LI ; Wu HONG ; Zuo-wei WANG ; Cheng-mei YUAN ; Ze-zhi LI ; Jia HUANG ; Chen ZHANG ; Ning-ning LI ; Zhi-guang LIN ; Yi-ru FANG
Journal of Forensic Medicine 2016;32(1):40-44
OBJECTIVE:
To explore the correlation between the interleukin-17 (IL-17) level of peripheral blood and aggression of bipolar mania.
METHODS:
Thirty-six patients of bipolar mania were selected as experimental group by DSM-IV-TR and received treatment with quetiapine and lithium. Thirty-six healthy volunteers with similar age and gender were selected as control group. The level of IL-17 at baseline in each group and the level of IL-17 in the experimental group after treatment for 2, 4 and 8 weeks were detected by ELISA.
RESULTS:
The level of IL-17 in experimental group at baseline, after treatment for 2 and 4 weeks were all significantly higher than that in control group. After 8 weeks treatment, there was no significant difference between the two groups (P > 0.05). After 2, 4 and 8 weeks treatment, the total score and aggression score of Young Mania Rating Score (YMRS) were significantly lower than the baseline level (P < 0.05). In experimental group, the level of IL-17 was positively correlated with the two scores of YMRS at baseline (P < 0.05).
CONCLUSION
Bipolar mania may be related to the up-regulation of IL-17. The level of IL-17 is related to the severity of manic symptoms at baseline, especially aggression symptom.
Aggression/drug effects*
;
Antipsychotic Agents/therapeutic use*
;
Biomarkers/blood*
;
Bipolar Disorder/drug therapy*
;
Case-Control Studies
;
Diagnostic and Statistical Manual of Mental Disorders
;
Double-Blind Method
;
Humans
;
Interleukin-17/metabolism*
;
Lithium Compounds/therapeutic use*
;
Quetiapine Fumarate/therapeutic use*
;
Treatment Outcome